Oncolytics Biotech Inc

Financials

Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.

Nachrichten

H.C. Wainwright bestätigt "Buy"-Rating für Oncolytics Biotech

Onkologie-Wirkstoff Pelareorep: Oncolytics plant FDA-Gespräch über Zulassungspfad bei Analkrebs

Oncolytics Biotech schließt ersten Schritt der Sitzverlegung nach British Columbia ab

Oncolytics launches phase 2 colorectal cancer study REO 033

Oncolytics beendet GOBLET-Studie und fokussiert sich auf US-Zulassungsverfahren

Oncolytics to wind down GOBLET study, focus on U.S. registration

FDA-Zulassung für Krebstherapie beflügelt Oncolytics-Aktie

Oncolytics Biotech stock soars after FDA grants Fast Track Designation

Pelareorep-Kombinationstherapie zeigt hohe Wirksamkeit bei Analkrebs

Pelareorep-atezolizumab shows promising results in anal cancer

Oncolytics Biotech plans to shift incorporation from Canada to Nevada

Oncolytics Biotech files patent application to extend pelareorep protection